Table 1 The relationship between P3H4 expression and clinicopathological characteristics in the TCGA cohort (n = 389)
From: P3H4 is correlated with clinicopathological features and prognosis in bladder cancer
| Characteristics | Expression of P3H4 mRNA, number (%) | ||
|---|---|---|---|
| High (n = 195) | Low (n = 194) | p value | |
| Age at diagnosis, years | 69.25 ± 10.18 | 66.39 ± 10.87 | 0.008 |
| Gender | 0.053 | ||
| Male | 136 (69.74) | 152 (78.35) | |
| Female | 59 (30.26) | 42 (21.65) | |
| BMI | 26.71 ± 4.78 | 27.42 ± 6.99 | 0.277 |
| Race category | 0.001 | ||
| White | 163 (87.63) | 145 (77.54) | |
| Black or African American | 13 (6.99) | 9 (4.81) | |
| Asian | 10 (5.38) | 33 (17.65) | |
| Angiolymphatic invasion | 0.181 | ||
| Yes | 77 (57.04) | 64 (48.85) | |
| No | 58 (42.96) | 67 (51.15) | |
| Extracapsular extension | 0.937 | ||
| Yes | 35 (44.30) | 31 (43.66) | |
| NO | 44 (55.70) | 40 (56.34) | |
| Karnofsky performance score | 84.33 ± 12.46 | 80.67 ± 15.39 | 0.146 |
| Histologic grade | 0.001 | ||
| High | 191 (98.45) | 174 (90.63) | |
| Low | 3 (1.55) | 18 (9.38) | |
| Lymph node metastasis | 0.454 | ||
| Yes | 59 (38.31) | 53 (42.74) | |
| No | 95 (61.69) | 71 (57.26) | |
| Tumor histologic subtype | 0.011 | ||
| Non-papillary | 141 (73.82) | 119 (61.66) | |
| Papillary | 50 (26.18) | 74 (38.34) | |
| Metastasis | 0.154 | ||
| M0 | 79 (91.86) | 110 (97.35) | |
| M1 | 7 (8.14) | 3 (2.65) | |
| AJCC stage | 0.006 | ||
| I | 0 (0) | 1 (0.52) | |
| II | 49 (25.13) | 79 (41.15) | |
| III | 75 (38.46) | 55 (28.65) | |
| IV | 71 (36.41) | 57 (29.69) | |